"AMBS" - Most Undervalued Micro Cap BioTech
Recently signed a development deal with Becton Dickinson for a diagnostic test to diagnose early stage Alzheimer's. Potential $500,000,000 in annual revenues.
P.s. Stock is currently trading under a nickle. Noted bio-tech analyst Jason Napadano values the company at .25 currently. Google his Seeking Alpha articles about the company and its patented MANF technology.
If Becton Dickinson is successful in developing the company's Lympro test that alone would value the company at $1.00/share.
The company's patented MANF technology could be worth many times that amount.